PYY plays a key role in the resolution of diabetes following bariatric surgery in humans

Claudia Guida a, Sam D. Stephen a, Michael Watson d, Niall Dempster a, Pierre Larrauri b, Thomas Marjot d, Tamsin Cargill d, Lisa Rickers e, Michael Pavlides f,g, Jeremy Tomlinson a, Jeremy F.L. Cobbold d, Chun-Mei Zhao c, Duan Chen c, Fiona Gribble b, Frank Reimann b, Richard Gillies e, Bruno Sgromo e, Patrik Rorsman a, John D. Ryan d,**,1, Reshma D. Ramracheya a,**,1

a Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, UK
b Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
c Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway
d Translational Gastroenterology Unit, University of Oxford, Oxford, UK
e Oxford Bariatric Service, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
f Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, UK
g Oxford NIHR Biomedical Research Centre, Oxford, UK

Abstract

Background: Bariatric surgery leads to early and long-lasting remission of type 2 diabetes (T2D). However, the mechanisms behind this phenomenon remain unclear. Among several factors, gut hormones are thought to be crucial mediators of this effect. Unlike GLP-1, the role of the hormone peptide tyrosine tyrosine (PYY) in bariatric surgery in humans has been limited to appetite regulation and its impact on pancreatic islet secretory function and glucose metabolism remains under-studied.

Methods: Changes in PYY concentrations were examined in obese patients after bariatric surgery and compared to healthy controls. Human pancreatic islet function was tested upon treatment with sera from patients before and after the surgery, in presence or absence of PYY. Alterations in intra-islet PYY release and insulin secretion were analysed after stimulation with short chain fatty acids (SCFAs), bile acids and the cytokine IL-22.

Findings: We demonstrate that PYY is a key effector of the early recovery of impaired glucose-mediated insulin and glucagon secretion in bariatric surgery. We establish that the short chain fatty acid propionate and bile acids, which are elevated after surgery, can trigger PYY release not only from enteroendocrine cells but also from human pancreatic islets. In addition, we identify IL-22 as a new factor which is modulated by bariatric surgery in humans and which directly regulates PYY expression and release.

Interpretation: This study shows that some major metabolic benefits of bariatric surgery can be emulated ex vivo. Our findings are expected to have a direct impact on the development of new non-surgical therapy for T2D correction.

© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Bariatric surgery, Diabetes, PYY, IL-22, Gut hormones, Pancreatic hormone secretion

1. Introduction

Bariatric surgery results in rapid and durable reversal of type 2 diabetes (T2D) and associated metabolic benefits in man [1]. Changes in gut hormones play a critical role in surgery-induced metabolic improvements, which are independent of weight loss [2]. In particular, post-operative elevation in the incretin hormone GLP-1, has been reported to contribute to appetite suppression and improved glycaemic control [2]. However, recent studies done in rodents and humans have revealed the existence of GLP-1-independent mechanisms, indicating that multiple cofactors mediate the metabolic effects of surgery [3–7]. Moreover, increased levels of...
Research in context

Evidence before this study

Bariatric surgery are weight loss interventions which result in rapid and durable reversal of type 2 diabetes (T2D) in man. Changes in gut hormones play a critical role in surgery-induced metabolic improvements. The gut hormone, GLP-1 has been so far considered as the ‘holy grail’ of this phenomenon although a number of studies have reported that the beneficial effect of the surgery on glucose homeostasis may not depend on GLP-1, thus challenging its unique role. Like GLP-1, the release of the gut hormone PYY increases after bariatric surgery. A common consensus posits that the main effect of this elevation in humans is on appetite regulation and weight loss post operatively. However, latest evidence from studies done in rodents has shown that, PYY plays a major role in glucose homeostasis and restoration of impaired islet function in severely diabetic rats following Roux-En-Y gastric bypass (RYGB). To date, the relationship between elevated circulating PYY and the metabolic benefits of bariatric surgery on islet secretory function has not been established in humans. Moreover, the impact of factors altered by the surgery on PYY elevation is not been fully characterized in man.

Added value of this study

Here we have examined the changes in PYY concentrations six months after bariatric surgery in obese patients compared with healthy control subjects, and their effects on human islet functions. Using a translational approach that combines blood samples from patients with T2D before and after surgery and isolated donor human pancreatic islets, we demonstrate a significant effect of PYY on the improvement of islet secretory function post-surgery. We establish that the short chain fatty acid propionate and bile acids, which are elevated after surgery, can trigger PYY release not only from enteroendocrine cells but also from human pancreatic islets. In addition, we identify IL-22 as a new factor which is modulated by bariatric surgery and which may directly regulate PYY expression and release, elucidating some of the mechanisms behind increased PYY concentrations after bariatric surgery in humans.

Implications of all the available evidence

This study demonstrates that the metabolic benefits of bariatric surgery on islet secretory functions can be emulated ex vivo, giving rise to the possibility of identifying the critical mediators of these effects. Our findings that the gut hormone PYY mediates some key anti-diabetic effects of bariatric surgery imply that a pharmacological agent enhancing PYY release or its action could provide an effective and non-surgical therapy for T2D. Moreover, the identification of factors specifically triggering PYY induction both systemically and within the islets, may pave the way for an alternative cure to peptide therapeutics, thus overcoming their inherent weaknesses, like poor pharmacokinetic properties and stabilities, and yet achieving the same benefits for the treatment of diabetes.

another intestinal hormone called peptide tyrosine tyrosine (PYY) have been reported following bariatric surgery. This peptide hormone was found to be central in the reversal of hyperglycaemia and restoration of impaired insulin release following Roux-en-Y gastric bypass (RYGB) in a rat model of T2D [8].

Both fasting and postprandial PYY levels increase significantly within just one-week of RYGB or sleeve gastrectomy (SG) in obese patients, and remain elevated after 1 year [9–11]. These changes are associated with normalization of fasting glucose levels, and improved blood pressure, hypercholesterolemia and hypertriglyceridemia [12]. Chronic treatment of human isolated islets from diabetic and non-diabetic donors with exogenous PYY enhances glucose-mediated insulin secretion and improves suppression of glucagon, suggesting a direct effect of PYY on the correction of human diabetes [8,13]. However, the relationship between elevated circulating PYY and the metabolic benefits of bariatric surgery on islet secretory function and diabetes reversal has not been explored in humans.

PYY is mainly secreted from the L-cells of the ileum and colon in response to food intake and, to a lesser extent, it is also expressed in the delta-, PP- and alpha-cells of the pancreatic islets [13]. In clear contrast to healthy islets, PYY content has recently been shown to be reduced by 50% in islets from the Goto-Kakizaki (GK) rat model of T2D, suggesting a role of islet-derived PYY in health and diabetes [13]. Moreover, consistent with the changes in circulating levels, PYY content in islets is markedly increased following RYGB in diabetic rats [13], potentially contributing to RYGB-induced restoration of impaired islet morphology and function. Several factors including accelerated nutrient delivery to the intestine are likely to stimulate PYY secretion following weight-loss surgery. Emerging evidence also suggests that alteration in bile acids, and the intestinal microbiota and their metabolic products can induce PYY release from enteroendocrine cells [14–17]. However, whether they can also modulate secretion of PYY from pancreatic islets, especially in humans is not known. One of the well-described effects of bariatric surgery is a reduction in the chronic systemic inflammation associated with obesity. Indeed, levels of inflammatory cytokines, such as IL-6 and TNFα decrease after bariatric surgery [18–20]. Unlike other cytokines, interleukin-22 (IL-22), a small cytokine mainly produced by Th1, Th17, Th22 and ILC3 cells, has been shown to alleviate metabolic disorders in mice and protect pancreatic islet properties beyond its immunological functions [21,22]. Importantly, infusion of IL-22 in diet-induced obese mice has been shown to result in elevated circulating PYY levels, which in turn reduces food consumption. To date, the role of IL-22 in weight-loss surgery and diabetes remission in man has not been explored, and its potential impact on islet-derived PYY has not been determined.

Here we have examined the changes in PYY concentrations six months after bariatric surgery in obese patients compared with healthy control subjects, and whether they can influence human islet secretory functions. In addition, we have assessed the impact of short chain fatty acids and bile acids on PYY release and glucose-mediated insulin secretion from isolated pancreatic human islets. Finally, we have explored alterations in plasma IL-22 concentrations following bariatric surgery in humans and modulation of PYY release from pancreatic islets by IL-22.

2. Materials and methods

2.1. Patients

All patients undergoing bariatric surgery (sleeve gastrectomy or RYGB) for morbid obesity have been recruited into the Oxford GI Biobank (Gastrointestinal Illness in Oxford: prospective cohort for outcomes, treatment, predictors and biobanking with ethical approval from Yorkshire & The Humber - Sheffield Research Ethics Committee, REC Ref:11/YH/0020 and 16/YH/0247) REC Ref:11/YH/0020 and 16/YH/0247), since November 2014. Written informed consent was obtained from all study subjects. Blood samples were collected on the day of surgery, and at 6 and 12 months post-operatively, along with detailed clinical information. Pre-operation samples were taken under fasting conditions,
while follow up samples were non-fasting, owing to the logistics of starving post-surgical patients, and afternoon clinic visits. However, the timing of blood sampling from the patients is expected to have minimal or negligible effects on islet hormone secretion. Patient characteristics are outlined in Table S1. Healthy control samples were obtained from the Oxford Centre for Clinical Magnetic Resonance Research (OCMR; Non-Invasive and Comprehensive Liver Assessment (NICOLA) study; REC Ref13/SC/0243), details outlined in Table S1.2.

2.2. Animals

Female C57BL6j mice (Charles River, US), aged 16–20 weeks, were used for islet functional studies and female mice bred in house on a C57BL/6 background, aged 16 to 24 weeks were used for colonic primary culture. Adult male 16–20 weeks-old Wistar rats as normoglycaemic controls and age and sex matched diabetic GK rats (Taconic, Denmark) were used as a model of type 2 diabetes. Data from experiments done in mice and rats are not cross compared with data generated from rats. All animal experiments were conducted in accordance with the UK Animals Scientific Procedures Act (1986) under the UK Home Office Project License 70/7824 and were approved by the University of Cambridge Animal Welfare and Ethical Review Body.

2.3. Islet isolation

Mouse islets were isolated by liberase (Sigma-Aldrich Ltd., Gillingham, UK) digestion as described previously [23]. Human pancreases were obtained with ethical approval and clinical consent from non-diabetic donors. Islets were isolated in the Diabetes Research & Wellness Foundation Human Islet Isolation Facility by collagenase digestion (Serva) using modified versions of published protocols [24]. The donor isolated human islets that were used for secretion studies were obtained with research consent via the DRWF Human Islet Isolation Facility at which was established in 2006 in the Oxford Centre for Diabetes, Endocrinology, and Metabolism in Oxford. The clinical islet isolation facility is a purpose built, clean-room laboratory, licensed by the UK Tissue Authority for the aseptic production of pancreatic islet cells from cadaveric donor pancreas. It plays a pivotal role in the supply of islets within the UK Islet Transplant Consortium (UKITC) for the delivery of an NHS funded national therapy for the treatment of type 1 diabetes in patients who have unstable diabetes with severe complications. When islets cannot be transplanted and where there is research consent, the isolated islets are made available for high quality diabetes research projects. Human islets were used for experiments as they became available. The robustness of each islet preparation is evaluated by the glucose-mediated insulin secretion index, which is calculated by dividing the mean insulin secretion at 20 mM glucose (stimulatory concentration) by that at 1 mM glucose (basal concentration). Thus, a prep which is not glucose-responsive is regarded as poor quality and one with at least a two-fold elevation in insulin secretion in response to 20 mM glucose, is regarded as good quality islets. Donor details are provided in Table S2.

2.4. Roux-en-Y gastric bypass model

Sham or RYGB surgery was performed on anesthetized rats as previously described [8]. Briefly, the intestine was transected 10 cm distal to the ligament of Treitz, creating a distal and a proximal end. The proximal end was anastomosed to the intestine and a gastric pouch was created (2–3% of total stomach). The distal end of the intestine was anastomosed to the gastric pouch in an end-to-side fashion. For sham operation the animals were opened through a midline incision and the viscera were gently manipulated.

2.5. Measurements of serum concentrations of PYY, GLP-1 and IL-22

Subject details are reported in Table S1.1 and S1.2. Human serum was kept at −80°C until determination of hormones. Total PYY and glucagon were measured by radioimmunoassay (Millipore and Eurodiagnostica). Total GLP-1 and insulin were assayed using human triplex kit (K15160C, Mesoscale Discovery). IL-22, IL-6 and IL-23 were measured in plasma and serum samples by Human IL-22 or IL-6 or IL-23 quantitative Elisa Kit (R&D systems).

For GK rats, blood was drawn from abdominal aorta at sacrifice under ad-libitum feeding conditions and processed as described previously [25]. IL-22 was measured in serum samples by means of mouse/rat IL-22 quantitative Elisa Kit (R&D systems).

2.6. Hormone secretion studies

Serum samples from the same patients before and 6 months after bariatric surgery were used (Table S1.1). Islets were pre-cultured for 72 h in RPMI (5 mM glucose) with the addition of 20% pooled serum in absence or presence of exendin (9–39; 1 μM; Bachem) or anti-PYY antibody (1:500; ab22663, Abcam) as previously described [8]. For each experiment, sera from two patients were pooled. Secretion experiments were set with 12 hand-picked and size-matched islets per tube (in triplicate). Islets were pre-incubated in Krebs-Ringer buffer (KRB) containing 2 mg/mL BSA and 3 mmol/l glucose for 1 h at 37 °C, followed by 1 h test incubation in KRB supplemented with glucose as indicated. Insulin and glucagon content were determined by radioimmunoassay (Millipore and Eurodiagnostica, respectively) according to the manufacturer’s instructions. To allow comparison between experiments, secretion data are presented as mean percent basal, where basal is secretion at 1 mM glucose.

Secretion experiments under acute or chronic conditions were performed as previously reported [13].

2.7. Measurements of PYY release from islets

20 islets per condition were cultured in 500 μL medium in absence or presence of propionate, butyrate and acetate (1 mM; Sigma-Aldrich) or GPRBAR-A (30 μM; Sigma-Aldrich) or recombinant IL-22 (100 ng/mL; R&D systems), each condition was set in triplicates. After the incubation time, islets and medium were collected separately and stored at −20 °C until determination of hormones. Total PYY was measured in islet and in the medium by radioimmunoassay (Millipore (human) and Phoenix Pharmaceuticals (mouse) according to the manufacturer’s instructions. PYY release was normalized over the intra-islet PYY content to minimize any variations due to differences in islet size. Analysis of intra-islet PYY content only was performed in parallel to ensure no specific effect of the treatment on the total PYY levels in islets.

2.8. Gene expression analysis in colonic primary culture

Colonic primary cultures were prepared as previously described [26,27] Colon and rectum were quickly isolated from mice sacrificed by cervical dislocation, washed thoroughly with PBS and cleaned of their outer muscle layer. Minced tissue was digested with 0.4 mg/mL Collagenase XI (Sigma-Aldrich) at 37°C to isolate crypts. Resuspended crypts were plated on Matrigel coated wells in culture media (DMEM high glucose supplemented with FBS10%, l-glutamine (2 mM), penicillin (100 U/mL), streptomycin (0.1 mg/mL) and Y27632 (10 μM, Tocris)). Plated crypts were washed the day after with fresh media and treated for 72 h accordingly in duplicates, changing the media after the first 24 h. Media was removed and replaced by Trizol (Sigma) and RNA extracted using manufacturer’s protocol and DNA removed incubating RNA for 20 min at 37°C with DNase I (Invitrogen). 200 ng of RNA were reverse transcribed (High capacity cDNA Reverse Transcription kit,
Thermo Fisher) and qPCR using Taqman probes and Taqman Fast universal Master mix (Life technologies) was performed on an ABIQuantStudio 7 (ThermoFisher Scientific) for Pyy, Cgc and β-actin (Mm00520716, Mm0081714 and Mm02619580, Life technologies). Data was analysed using the \( \Delta \Delta CT \) method with β-actin as reporter gene and using the mean of the control duplicates as control. Statistical difference was evaluated using a Dunn to control test from three different experiments done in duplicates (R, PMCMR package).

2.9. PYY peptide quantification in colonic primary culture

The protein fraction from the Trizol extraction was extracted: after the DNA precipitation, protein are precipitated with 1.5 v/v cold acetone for 10 min, and the protein pellet after a 12,000 g 10 min centrifugation. Peptides resuspended in 0.1% formic acid are then purified with 800μL ACN80% (in water) and peptides collected in the supernatant after 12,000 g 10 min centrifugation and dried by vacuum centrifugation. Peptides resuspended in 0.1% formic acid are then purified using a solid phase extraction (Oasis prime HLB, Waters) and eluted in 2×30 μL 60% MetOH, 30% H2O, 10% acetic acid and diluted with 75 μL 0.1% formic acid in solution.

Peptides were analysed on an H-Class Acquity (Waters) attached to a TQ-XS triple quadrupole mass spectrometer (Waters). Sample (20 μL) was injected onto a 2.1 × 50 mm 1.8 μm particle HSS T3 Acquity column held at 60 °C and flowing at 350 μL/min. Gradient starting condition was 99% A (0.1% formic acid in water v/v) and 1% B (0.1% formic acid in ACN). Starting conditions were held for 0.25 min before raising to 50% B over 7 min. The column was flushed with 90% B for 1 min before returning to starting conditions. The total time of each analysis was 10 min, with the first 0.75 min and last 2 min diverted to waste. Mass spectrometry conditions involved targeting four peptides using the transition and collision energy details given below:

| Peptide          | Q1 (m/z) | Q3 (m/z) | Collision energy (eV) | Dwell time (ms) |
|------------------|----------|----------|-----------------------|----------------|
| PYY 1–36 1       | 664.4    | 732.4    | 20                    | 25             |
| PYY 1–36 2       | 664.4    | 754.4    | 20                    | 25             |
| PYY 3–36 1       | 707.7    | 847.5    | 20                    | 25             |
| PYY 3–36 2       | 707.7    | 871.9    | 22.5                  | 25             |
| Oxyntomodulin 1  | 742.6    | 680.7    | 22.5                  | 25             |
| Oxyntomodulin 2  | 742.6    | 923.7    | 22.5                  | 25             |
| GLP-II 1         | 943.0    | 1306.58  | 25                    | 25             |

The source parameters used included a positive electrospray ion voltage of 3.0 kV, gas flow of 1000 L/h, desolvation temperature of 600 °C and a cone voltage of 40 V. Peptide peak areas were integrated using the TargetLynx program associated with Masslynx V 4.2 (Waters).

2.10. Statistical analysis

Values are expressed as the mean ± standard error of the mean (SEM). The statistical significance of differences was evaluated by the Unpaired Student’s t-test assuming unequal variation when two groups were compared or by one way ANOVA and Bonferroni’s multiple comparison tests when multiple groups were compared. A p value of <0.05 was regarded as significant. Statistical analysis was performed using GraphPad Prism.

Correlation analysis was performed with Pearson's pairwise correlation test (GraphPad).

Fig. 1. Changes in PYY concentrations in human serum samples. Serum total PYY in healthy volunteers (n = 20) and in patients before and 6 months after bariatric surgery (n = 25). Data are presented as mean ± SEM. (One-way ANOVA for multiple comparison) *P < 0.05 for indicated comparison.

3. Results

3.1. Obese subjects have low circulating PYY levels, which are restored post-bariatric surgery

Serum total PYY levels were measured in obese patients before (mean ± SEM; BMI 47 ± 8.4) and six months after either gastric bypass or sleeve gastrectomy (SG; mean ± SEM; BMI 37.5 ± 7.4; p < 0.0001) and compared with healthy volunteers (mean ± SEM; BMI 22.24 ± 2.1) (Fig. 1). Serum PYY concentrations were 25% lower in obese individuals compared to healthy people (mean ± SEM in pg/mL; 125 ± 8.1 vs 164.5 ± 8.8, p-value = 0.0002). Following both RYGB and SG, serum PYY in obese patients increased to levels seen in normal-weight individuals. Total GLP-1 levels were not significantly changed by bariatric surgery (Fig. S1a). Circulating insulin levels, which were markedly raised in obese individuals, decreased post-operatively (Fig. S1b).

3.2. Improvement of human islet function post-surgery is mediated by PYY

Isolated human islets from three donors were cultured for 72 h in the absence and presence of serum collected from patients before and after bariatric surgery. Following the culture period, insulin and glucagon release were measured at low (1 mM) and high (20 mM) glucose concentrations. Islets exposed to pre-surgery serum exhibited a lack of insulin release in response to 20 mM glucose (Fig. 2a). In contrast, application of post-surgery serum also resulted in increased insulin content (Fig. 2b), in agreement with the effects of exogenously applied PYY on isolated islets [13]. Islets treated with the post-surgery serum also exhibited normal suppression of glucagon at 20 mM glucose (Fig. 2c). We hypothesized that humoral factors altered by surgery, including circulating gut hormones, mediate the improvements seen in insulin and glucagon secretion from islets. To further test the possible involvement of systemic GLP-1, the GLP-1 receptor antagonist exendin [9–39] was added to the serum during culture. Under these conditions, GLP-1 receptor blockade did not affect glucagon-mediated insulin secretion. To explore if PYY is the humoral factor mediating the beneficial effects of bariatric surgery on islet function in man, islets from human donors were co-incubated with the post-surgery serum and a PYY-specific antibody at a concentration demonstrated to react with the peptide [13]. Immuno-neutralization of PYY resulted in complete reversal of glucose-induced insulin release (Fig. 2a). Chronic treatment of human islets with post-surgery serum also resulted in increased insulin content (Fig. 2b), in agreement with the effects of exogenously applied PYY on isolated islets [13]. On the other hand, both inhibition of GLP-1 signaling and immunoneutralization of PYY showed a tendency to partially attenuate...
the effects of post-surgery serum on glucagon release (Fig. 2c). There was no change in islet glucagon content (Fig. 2d).

3.3. Which factors, altered by bariatric surgery, cause PYY elevation?

3.3.1. Propionate and bile acids mimic the effects of bariatric surgery by inducing pancreatic PYY release and potentiating insulin secretion

Bacterial-derived metabolites, such as short chain fatty acids in rodents and man following bariatric surgery [29,30] and can directly modulate PYY secretion from L-cells [31,32]. To test if SCFAs can also influence PYY release from islets ex vivo, mouse and human islets were treated with propionate, butyrate and acetate. Of the three SCFAs, only propionate resulted in a small but significant increase in PYY secretion at 72 h in both human and mouse islets (Fig. 3a and b). No difference in islet PYY content was observed between control and propionate treatment at any time point (data not shown). Chronic incubation of mouse islets with propionate also potentiated glucose-stimulated insulin secretion (Fig. S2a), in agreement with previous findings [33].

Alteration in the enterohepatic circulation of bile acids is thought to be another important mediator of the weight-independent benefits of bariatric surgery [34]. Like SCFAs, bile acids can induce GLP-1 and PYY release from enteroendocrine cells via activation of the bile acid receptor TGR5 [35] which is also expressed on pancreatic islets [36]. Incubation of human islets with GPBAR-A, a potent agonist of TGR5, had no effect on islet-derived PYY release (Fig. 3c) but resulted in enhancement of glucose-stimulated insulin secretion (Fig. S2b), recapitulating previous findings in rodents [36]. In contrast to human islets, GPBAR-A strongly elevated PYY secretion in mouse islets, and this effect was sustained even after prolonged incubation (Fig. 3d).

3.3.2. IL-22 is a new factor induced by bariatric surgery

A number of circulating inflammatory cytokines known to be elevated in obesity are reduced following bariatric surgery, possibly as a consequence of the substantial weight loss that occurs. IL-22 is an inflammatory mediator of the innate and adaptive immune response which also regulates adiposity and metabolic disorders [37]. Circulating IL-22 levels were assessed in healthy volunteers and obese patients before and six months after bariatric surgery. Compared to levels before surgery, a significant increase in IL-22 concentrations was observed in sera from post-surgery patients (Fig. 4a). A trend towards increased IL-22 levels was also found in obese individuals in comparison to healthy people. To test whether such elevation was conserved in rodents after bariatric surgery we also explored IL-22 concentrations in serum samples from lean, diabetic GK rats after RYGB or sham surgery. Compared to levels in the sham control sera, a more pronounced elevation in IL-22 concentrations was noted in sera from GK rats post-RYGB (Fig. S3a). In contrast to IL-22, circulating levels of IL-6 and IL-23 were not altered by the surgery in humans (Fig. 4b and c).

3.3.3. IL-22 modulates PYY expression and release from enteroendocrine cells and pancreatic islets

In our analysis the increase in circulating PYY after surgery correlates with the increase in circulating IL-22 levels (Pearson r: 0.73) (Fig. S3b). To test whether IL-22 directly induces PYY expression from enteroendocrine cells, mouse colonic primary cultures were treated with IL-22 for 6, 24, 48 and 72 h and Pyy mRNA levels were measured. Stimulation with IL-22 for 24 to 72 h significantly increased Pyy gene expression with the highest peak at 48 h incubation (Fig. 5a). Such
Elevation was further confirmed at protein levels in the colonic culture extracts by LC-MS (Fig. 5b).

In parallel, the effects of IL-22 on PYY release from pancreatic islets were studied. Twenty-four hours exposure of isolated mouse and human islets with the recombinant cytokine resulted in a small but significant increase in PYY release (Fig. 5c and d). Of note, while the presence of IL-22 receptors on human pancreatic islets has been documented, we were unable to detect IL-22 in isolated islets [38]. IL-22 has been associated with preservation of insulin secretion in isolated islets upon induction of cytokine-mediated oxidative and ER stress. However, under physiological conditions, it does not affect glucose-induced insulin release [22]. In line with this observation,

**Fig. 3.** Propionate and bile acids induce pancreatic PYY release. Human (donors n = 9) (a, c) and mouse (mice n = 3) (b, d) islets were incubated with 1 mM propionate, butyrate or acetate or 30 μM GPBAR-A for the indicated time length (included in culture medium). Ratio between total PYY in the medium and in the islets is reported. ***P < 0.001, *P < 0.05 for indicated comparison.

**Fig. 4.** IL-22 levels increase after bariatric surgery. Plasma IL-22 (a), IL-6 (b) and IL-23 (c) in healthy volunteers (n = 20) and in patients before and 6 months after bariatric surgery (n = 25). Data are presented as mean ± SEM. (One-way ANOVA for multiple comparison) **P < 0.001 for indicated comparison.
induced insulin and glucagon secretion that occurs post-surgery can be
ex vivo and pre- and post-surgery sera, we show that improved glucose-
humans has not been investigated previously. Using donor human islets
concentrations and improved islet function post bariatric surgery in
donors [13]. However, an association between increased circulating PYY
tiate glucose-dependent insulin secretion in human islets from diabetic
nous application of recombinant PYY has been demonstrated to poten-
tial, although not signifi

4. Discussion

A combination of factors, rather than a single one, is likely to account
for the compelling metabolic benefits associated with bariatric surgery.
PYY has been described as a classical weight loss-mediator and its role
in the metabolic benefits of surgery has largely been limited to its func-
tion as an appetite regulator. Here we show that, compared with levels
in healthy volunteers, total PYY levels are signifi

acute (1 h) and chronic (72 h) treatment of healthy mouse and human
islets with IL-22 did not affect glucose-induced insulin release (Fig. S4),
suggesting that a direct compensatory effec

emulated in vitro. In particular, prolonged exposure of islets with sera
post-surgery restored the glucose-mediated inhibition of glucagon se-
cretion, which was lacking in islets exposed to pre-surgery sera,
whereby glucose tended to stimulate glucagon secretion, an observa-
tion consistent with those reported in islets from patients with T2D
[28]. These findings demonstrate that bariatric surgery can influence
islet function via blood-borne factors, which remain conserved in
serum. We also report that immuno-neutralization of PYY leads to com-
plete reversal of surgery-induced improved insulin secretion and a par-
tial, although not signifi

in insulin content as previously reported following chronic exposure
of islets to recombinant PYY [13], implying that elevation of insulin con-
tent in islets may be crucial for ameliorating beta-cell secretory
properties.

In addition to elevating circulating PYY levels in the GK rats, gastric
bypass surgery also leads to an increase in pancreatic PYY content (com-
pared to sham-operated controls) [13], thus providing a local (intra-
islet) source of PYY that may directly affect islet secretory functions.
However, the mechanism behind PYY elevation in islets post-surgery
remains unknown. Bariatric surgery signifi

cant weight loss, a

C. Guida et al. / EBioMedicine 40 (2019) 67–76
73

Fig. 5. IL-22 induces PYY gene expression and PYY secretion in pancreatic islets and primary colonic culture. (a, b) Expression of PYY gene (a) and protein (b) in colonic primary mouse
culture non-treated (NT) or exposed to 100 ng/ml IL-22 for 6, 24, 48 and 72 h (mice n = 4). Data are presented as relative Pyy expression/protein to control (mean ± SEM). Human (b) and
mouse (c) islets were treated with 100 ng/ml IL-22 for 24 h. Ratio between total PYY in the medium and in the islets is reported. *P < 0.05 for indicated comparison.
in PYY release from mouse and human isolated islets. Although this delayed response cannot be fully explained, we speculate that it might be secondary to alteration in gene expression and expression of intermediate factors. In addition, the activation of the bile acid receptor TGR5 which is expressed on pancreatic beta-cells [36], results in a prominent induction of islet-derived PYY in mice. This effect was not observed in human islets, suggesting a possible species-specific impact of bile acid changes on gut-dependent PYY production. Bile acids are increasingly recognized as important regulators of lipid and glucose metabolism [45]. In patients, fasting and postprandial bile acid concentrations rise following RYGB, while conflicting results have been reported after SG [34,46]. Restoration of glucose-dependent insulin secretion post-surgery could be attributed to increased levels of bile acids since activation of the bile acid sensors FXR [47] and TGR5 [36] has been shown to enhance insulin release in isolated islets. Consistent with these reports, we observe that 1 h stimulation of TGR5 by the agonist GPBAR-A potentiates glucose-stimulated insulin secretion in human islets, even when the donor human islets were poorly responsive to glucose, probably due to their sub-optimal quality (purity -50%; viability -50%). Collectively these data indicate that propionate and bile acids can enhance glucose-induced insulin secretion both directly and indirectly via increased release of PYY from the gut and islets (Fig. 6).

Obesity and the metabolic syndrome are accompanied by a ‘low grade’ chronic inflammation, indicated by a well-characterized positive association between obesity indices and inflammatory markers, such as C reactive protein (CRP) and IL-6 [48]. Thus, weight loss triggered by bariatric surgeries is expected to lead to a reduction in the circulating levels of inflammatory mediators, often seen more than six months after the operation [18,19]. To date, there is a lack of consensus regarding the changes in IL-6 levels following weight-loss surgery. Whereas, some studies have documented a substantial post-operative decrease [49–51], Miller et al. has reported no significant changes in IL-6 six months after gastric bypass [20]. These latter reports are consistent with our findings in which IL-6 and IL-23 levels were unaffected by bariatric surgery in humans. On the other hand, post-surgery elevation in IL-22 that we observe here is a novel finding deserving further study.

Fig. 6. Increased PYY levels in circulation and in islets occur via several factors and jointly contribute to restoration of islet function after bariatric surgery. GSIS = glucose-stimulated insulin secretion.

BARIATRIC SURGERY

PROPIONATE

IL-22

BILE ACIDS

Systemic and intra-islet PYY

GSIS

hepatic steatosis induced by high fat diet [52]. Thus, it is plausible to speculate that its elevation after bariatric surgery might contribute to the improvement in steatosis and nonalcoholic fatty liver disease reported in patients [53].

Unlike other cytokines, IL-22 also protects pancreatic islets from oxidative and ER stress and preserves their secretory functions, whilst opposite effects are mediated by IL-23, a cytokine upstream of IL-22 [22]. Due to its unique role in alleviating metabolic disorders and its direct restorative effect on pancreatic beta-cells, IL-22 constitutes an important factor potentially mediating post-surgery anti-diabetic and beneficial metabolic effects. It is noteworthy that the GK rat represents a lean diabetic model. Nevertheless, IL-22 is highly elevated post-surgery in these rats, indicating that its physiological roles are independent of weight.

In line with previous reports, acute or chronic treatment islets isolated from healthy human donors with IL-22 failed to enhance insulin secretion, suggesting that IL-22 is not a potentiator of insulin secretion per se, but that it might act to preserve or restore islet function under stressful conditions. Yet it remains unknown if IL-22 has a direct effect on compromised islets from diabetic donors. Among its multiple positive influences on metabolic disease, IL-22 injection in obese mice leads to increased serum PYY levels which is thought to contribute to the reduction in food intake and weight [21]. This increase in PYY is likely to be caused by IL-22-mediated stimulation of PYY expression in enteroendocrine L-cells, as indicated by our data. We only detected a mild increase in islet-derived PYY, which on its own, may be too small to directly impact on islet hormone secretion. Thus, it is likely that under physiological conditions, IL-22 indirectly modulates insulin secretion mainly via elevation in PYY release from L-cells (Fig. 6). Taken together our data demonstrate that PYY is a critical humoral factor which mediates enhanced islet secretory function, thus contributing to diabetes remission in humans upon bariatric surgery. Whereas there is no way to differentiate between the contribution of circulating and islet-derived PYY, it is likely they both contribute to restore islet function and sustain this effect over long-term. We postulate that modulation of blood-borne factors such as propionate, bile acids and IL-22 can increase overall PYY levels, which may subsequently influence islet function, resulting in improved insulin and glucagon secretion. Due to shortage of human serum samples we did not analyse changes in PYY [3–36], which constitutes another major endogenous form of PYY likely to affect insulin release. Nevertheless, these findings provide new mechanistic links with key factors induced by bariatric surgery, restoration of impaired islet function and diabetes correction.

Bariatric surgery as a treatment option for type 2 diabetes (rather than for weight-loss alone) has been endorsed by 50 international health organizations. However, surgery remains invasive, irreversible and not suitable for all patients with T2D, highlighting the urgent need for medical therapies as alternatives. Using a unique translational research paradigm combining serum from patients before and following surgery with isolated human islets, our study demonstrates that the metabolic benefits of bariatric surgery can be emulated ex vivo, giving rise to the possibility of identifying the critical mediators of these effects. While our analysis focuses on the regulation of PYY and its effects on islet secretory functions, it is likely that other factors also contribute to achieve the metabolic benefits elicited by surgery, including improvements in peripheral tissue insulin sensitivity or tissue glucose clearance, and a combination of therapies may be required to successfully overcome the need for this invasive and irreversible procedure. Particularly, we foresee that the addition of PYY analogues to other incretin mimetics would potentiate and sustain their long-term efficacy. Moreover, the identification of factors specifically triggering PYY induction both systematically and within the islets, may pave the way for an alternative cure to peptide therapeutics, thus overcoming their inherent weaknesses, like poor pharmacokinetic properties and stabilities, and yet achieving the same benefits for the treatment of diabetes.
Acknowledgments

We thank Prof. John Johnson and his team for the provision of donor human islets. We thank Magnus K.Olsen, Hanne-Linne Rubben and Helene Johannessen for their assistance with blood sampling and RYGB surgery on the GK rats. We are also grateful to Dr. Anne Clark for her intellectual input in the project.

Funding sources

This work was supported by the Novo Nordisk Oxford Fellowship Programme, Diabetes UK RD Lawrence Fellowship and Non Clinical Research Fellowship from Wolfson College, Wellcome Trust ISSF funding, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and European Association for the Study of the Liver and the Swedish Research Council and the Joint Programme of the Medical Faculty of Norwegian University of Science and Technology (NTNU) and St. Olavs University Hospital. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Funding sources had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Declaration of interests

Dr. Dempster reports grants from the University of Oxford Novo Nordisk Clinical Research Fellowship, during the conduct of the study. Dr. Larraufie reports grants from Wellcome Trust and UK government (MRC), during the conduct of the study. Dr. Gribble reports personal fees from NovoNordisk, during the conduct of the study. Drs. Dempster, Margolskee RF, Drucker DJ, Aguirre V. Effects of Roux-en-Y gastric bypass and sleeve gastrectomy on beta cell function and glucose tolerance after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 2011;7(5):618–26.

Author contributions

CG designed and performed the experiments, analysed the data and wrote the manuscript. SDS and PL performed experiments and analysed the data, MW, ND, TM, TC and LR collected human samples, MP, JT, JFLC, RG and BS coordinated provision of samples and study design, CMZ and DC provided the RYGB rat model and reviewed the manuscript, FR, FG and BS coordinated provision of samples and study design, CMZ and BS coordinated provision of samples and study design, CMZ and BS provided the RYGB rat model and reviewed the manuscript, FR, FG and BS provided the RYGB rat model and reviewed the manuscript.

References

[1] Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122(3):248–56 e5.
[2] Holst J, Madshid S. Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surg Obes Relat Dis 2016;12(6):1236–42.
[3] Mokadem M, Zechnier JF, Margolleske RF, Drucker DJ, Aguirre V. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol Metab 2014;3(2): 191–201.
[4] Wilson-Perez HE, Chambers AP, Ryan KK, Li B, Sandoval DA, Stoffers D, et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes 2013;62(7):2380–5.
[5] Pouranaras DJ, Osborne A, Hawkins SC, Mahon D, Gheare MA, Bloom SR, et al. The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study. Obes Surg 2010;20(1):56–60.
[6] Clements RH, Gonzalez QH, Long CL, Wittwer G, Laws HL. Hormonal changes after Roux-en-Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg 2004;70(1):1–4 (discussion -5).
[7] Ruderman N, Gagner M, Grileschi P, Kini S, Fukuyama S, Feng J, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004;240(2):236–42.
[8] Ramracheya RD, McCoiluch LJ, Clark A, Wiggins D, Johannesen H, Olsen MK, et al. PY-Day independent Restoration of Impaired Insulin and Glucagon Secretion in Type 2 Diabetes following Roux-En-Y Gastric Bypass Surgery. Cell Rep 2016;15(5):944–50.
[9] Karamanols SN, Vagenas K, Kallarentos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008;247(3):401–7.
[10] Peterli R, Wolnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009;250(2):234–41.
[11] Papamargaritis D, Le Roux CW, Sioka E, Koukoulis G, Tzovaras G, Zacharoulis D. Changes in gut hormone profile and glucose homeostasis after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis 2013;9(2):192–201.
[12] Federico A, Dallio M, Tolone S, Gravina AG, Patrone V, Romano M, et al. Gastrointestinal hormones, intestinal microbiota and metabolic homeostasis in obese patients: effect of bariatric surgery. In Vivo 2016;30(3):321–30.
[13] Gribble FM, McCoiluch LJ, Godzagar M, Stephen SD, Baker C, Basco D, et al. Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intracellular PYY. Diabetes Obes Metab 2018;20(3):571–81.
[14] Bhutta HY, Rajpal N, White W, Freedberg M Jr, Liu Y, Way J, et al. Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats. PLoS One 2015;10(3):e0122273.
[15] Trenamori V, Karlsson F, Werling M, Stahlman M, Kovatcheva-Datchary P, Olbers T, et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes in the human gut microbiome contributing to fat mass regulation. Cell Metab 2015;22(2):228–38.
[16] den Besten G, van Eeunen K, Groen AK, Venema K, Reijnoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013;54(9):2325–40.
[17] Larraufie P, Dare J, Lapaquette N, Blottiere HM. TLR ligands and butyrate increase Py expression via two distinct but inter-regulated pathways. Cell Microbiol 2017;19(2).
[18] Rao SR. Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res 2012;61(8):789–807.
[19] Viana EC, Araujo-Dasilio RL, Miguel CP, Bressan J, Lemos EM, Moyses MR, et al. Gastric bypass and sleeve gastrectomy: the same impact on IL-6 and TNF-alpha. Prospective clinical trial. Obes Surg 2013;23(8):1522–61.
[20] Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 2011;7(5):618–24.
[21] Wang X, Ota N, Manzanillo P, Katz L, Zavala-Soto J, Eidenschink E, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 2014;514(7521):237–41.
[22] Hasnain SZ, Borg DJ, Harcourt BE, Tong H, Sheng YH, Ng CP, et al. Glycemic control in L cells: a primary cell study. Cell Metab 2008;8(6):532–42.
[23] Olofsson CS, Salehi A, Holm C, Rorsman P. Palmitate increases L-type Ca2+ currents and the size of the readily releasable granule pool in mouse pancreatic beta-cells. J Physiol 2004;557(Pt 3):935–46.
[24] Psichas A, Tolhurst G, Brighton CA, Gribble FM, Reimann F. Mixed primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells. JoVE 2017;122.
[25] Hasnain SZ, Borg DJ, Harcourt BE, Tong H, Sheng YH, Ng CP, et al. Glycemic control in L cells: a primary cell study. Cell Metab 2008;8(6):532–42.
[26] Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 2011;7(5):618–24.
[27] Wang X, Ota N, Manzanillo P, Katz L, Zavala-Soto J, Eidenschink E, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 2014;514(7521):237–41.
[28] Hasnain SZ, Borg DJ, Harcourt BE, Tong H, Sheng YH, Ng CP, et al. Glycemic control in L cells: a primary cell study. Cell Metab 2008;8(6):532–42.
[29] Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 2011;7(5):618–24.
[30] Wang X, Ota N, Manzanillo P, Katz L, Zavala-Soto J, Eidenschink E, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 2014;514(7521):237–41.
[31] Hasnain SZ, Borg DJ, Harcourt BE, Tong H, Sheng YH, Ng CP, et al. Glycemic control in L cells: a primary cell study. Cell Metab 2008;8(6):532–42.
[32] Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 2011;7(5):618–24.
[33] Wang X, Ota N, Manzanillo P, Katz L, Zavala-Soto J, Eidenschink E, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 2014;514(7521):237–41.
[34] Hasnain SZ, Borg DJ, Harcourt BE, Tong H, Sheng YH, Ng CP, et al. Glycemic control in L cells: a primary cell study. Cell Metab 2008;8(6):532–42.
Pingitore A, Chambers ES, Hill T, Maldonado IR, Liu B, Bewick G, et al. The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro. Diabetes Obes Metab 2017;19(2):237–65.

Albaugh VL, Banan B, Ajouz H, Abumrad NN, Flynn CR. Bile acids and bariatric surgery. Mol Aspects Med 2017;56:75–89.

Kumar DP, Rajagopal S, Maffioli S, Mirshahi F, Grider JR, Murthy KS, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic beta cells. Biochem Biophys Res Commun 2012;427(3):941–8.

Fondevilla CA, Lagarde M, Schick F, Lauerbach F, Piqueras J, et al. Effects of Roux-en-Y gastric bypass and sleeve gastrectomy on insulin sensitivity and inflammation. J Gastroenterol Hepatol 2017;32(4):494–500.

Yang L, Zhang Y, Wang L, Fan F, Zhu L, et al. Amelioration of high-fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J Hepatol 2010;53(2):339–47.

Nostedt IJ, Switzer NJ, Gill RS, Dang J, Birch DW, de Gara C, et al. The effect of Bariatric Surgery on the Spectrum of Fatty Liver Disease. Can J Gastroenterol Hepatol 2016;2016:2059245.